Laparoscopic Therapy of Endometrioma: Sclerotherapy vs Cystectomy in Patients With Unfinished Rep… (NCT05801523) | Clinical Trial Compass
UnknownNot Applicable
Laparoscopic Therapy of Endometrioma: Sclerotherapy vs Cystectomy in Patients With Unfinished Reproductive Plans
Czechia160 participantsStarted 2023-02-01
Plain-language summary
The aim of this prospective randomized study is to compare laparoscopic sclerotherapy to cystectomy in following: AMH dynamics, endometrioma recurrence, complications, pregnancy rate, assisted reproduction methods success rate, live birth rate
Who can participate
Age range
18 Years – 40 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* IOTA benign endometrioma
* bilateral or unilateral endometrioma measuring 30 or more milimeters
* patients with unfinished reproductive plans
Exclusion Criteria:
* bilateral recurrence of endometrioma
* recurrent endometrioma if the other ovary is not present or patient had cystectomy on the other ovary
* suspision for ovarian malignancy
* signs of inflammatory pelvic disease
* disagreement with participation in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
AMH dynamics
Timeframe: Measuring change in AMH levels immediately before surgery and than at 6 and 12 months after surgery
2
endometrioma recurrence
Timeframe: Measuring change of endometrioma size (in case of recurrence) at 3, 6, 12 and 24 months after surgery
3
complications
Timeframe: 0-12 months
Trial details
NCT IDNCT05801523
SponsorInstitute for the Care of Mother and Child, Prague, Czech Republic